{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:07:49Z","timestamp":1787170069717,"version":"build-2736575974"},"reference-count":28,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jdiacomp.2025.109068","type":"journal-article","created":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T18:44:30Z","timestamp":1746989070000},"page":"109068","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Age different effects of SGLT2 inhibitors on body composition in individuals with type 2 diabetes: A retrospective cohort study"],"prefix":"10.1016","volume":"39","author":[{"given":"Kengo","family":"Miyoshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohisa","family":"Aoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saori","family":"Kameda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagisa","family":"Ishibashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Kadowaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimasa","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2025.109068_bb0005","series-title":"IDF diabetes atlas","author":"International Diabetes Federation","year":"2021"},{"key":"10.1016\/j.jdiacomp.2025.109068_bb0010","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the global burden of disease study 2021","volume":"402","author":"Ong","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2025.109068_bb0015","doi-asserted-by":"crossref","first-page":"F889","DOI":"10.1152\/ajprenal.00267.2015","article-title":"Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus","volume":"309","author":"Abdul-Ghani","year":"2015","journal-title":"American Journal of Physiology-Renal Physiology"},{"key":"10.1016\/j.jdiacomp.2025.109068_bb0020","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2025.109068_bb0025","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2025.109068_bb0030","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.2337\/dc24-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2025.109068_bb0035","doi-asserted-by":"crossref","first-page":"5952","DOI":"10.3390\/jcm12185952","article-title":"Association between the prognostic nutritional index and chronic microvascular complications in patients with type 2 diabetes mellitus","volume":"12","author":"Aktas","year":"2023","journal-title":"JCM"},{"key":"10.1016\/j.jdiacomp.2025.109068_bb0040","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.clnesp.2024.07.016","article-title":"Effect of sodium glucose co-transporter 2 inhibitor use on anthropometric measurements and blood glucose in obese and non-obese type 2 diabetic patients","volume":"63","author":"Dedemen","year":"2024","journal-title":"Clinical Nutrition ESPEN"},{"key":"10.1016\/j.jdiacomp.2025.109068_bb0045","doi-asserted-by":"crossref","first-page":"101421","DOI":"10.37349\/eemd.2025.101421","article-title":"Waist-to-height ratio as a novel marker of metabolic syndrome in patients with type 2 diabetes mellitus","volume":"10","author":"Basaran","year":"2025","journal-title":"Explor Endocr Metab Dis"},{"key":"10.1016\/j.jdiacomp.2025.109068_bb0050","doi-asserted-by":"crossref","DOI":"10.15562\/bmj.v7i3.806","article-title":"Mean platelet volume (MPV) as an inflammatory marker in type 2 diabetes mellitus and obesity","volume":"7","author":"Aktas","year":"2018","journal-title":"Bali Med J"},{"key":"10.1016\/j.jdiacomp.2025.109068_bb0055","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1590\/1806-9282.20220271","article-title":"Relationship between frailty, according to three frail scores, and clinical and laboratory parameters of the geriatric patients with type 2 diabetes mellitus","volume":"68","author":"Akan","year":"2022","journal-title":"Rev Assoc Med Bras"},{"key":"10.1016\/j.jdiacomp.2025.109068_bb0060","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s40266-023-01042-4","article-title":"Repurposing drugs for diabetes mellitus as potential pharmacological treatments for sarcopenia \u2013 a narrative review","volume":"40","author":"Witham","year":"2023","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jdiacomp.2025.109068_bb0065","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s13300-023-01481-7","article-title":"The effects of sodium\u2013glucose cotransporter 2 inhibitors on body composition in type 2 diabetes mellitus: a narrative review","volume":"14","author":"Jahangiri","year":"2023","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.jdiacomp.2025.109068_bb0070","doi-asserted-by":"crossref","first-page":"e0279889","DOI":"10.1371\/journal.pone.0279889","article-title":"Effect of SGLT-2 inhibitors on body composition in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials","volume":"17","author":"Pan","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.jdiacomp.2025.109068_bb0075","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jamda.2019.12.012","article-title":"Asian working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment","volume":"21","author":"Chen","year":"2020","journal-title":"J Am Med Dir Assoc"},{"key":"10.1016\/j.jdiacomp.2025.109068_bb0080","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/j.clnu.2023.10.004","article-title":"Sodium-glucose co-transporter 2 inhibitors and sarcopenia: a controversy that must be solved","volume":"42","author":"Afsar","year":"2023","journal-title":"Clin Nutr"},{"key":"10.1016\/j.jdiacomp.2025.109068_bb0085","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/jcsm.12814","article-title":"Extracellular lipidome change by an SGLT2 inhibitor, luseogliflozin, contributes to prevent skeletal muscle atrophy in db\/db mice","volume":"13","author":"Bamba","year":"2022","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jdiacomp.2025.109068_bb0090","doi-asserted-by":"crossref","first-page":"100176","DOI":"10.1016\/j.jlr.2022.100176","article-title":"The SGLT2 inhibitor dapagliflozin promotes systemic FFA mobilization, enhances hepatic \u03b2-oxidation, and induces ketosis","volume":"63","author":"Wallenius","year":"2022","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jdiacomp.2025.109068_bb0095","first-page":"H117","article-title":"Treatments for skeletal muscle abnormalities in heart failure: sodium-glucose transporter 2 and ketone bodies","volume":"322","author":"Takada","year":"2022","journal-title":"Am J Phys Heart Circ Phys"},{"key":"10.1016\/j.jdiacomp.2025.109068_bb0100","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","volume":"124","author":"Merovci","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jdiacomp.2025.109068_bb0105","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/jdi.12985","article-title":"Ipragliflozin, a sodium\u2013glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: a randomized clinical trial","volume":"10","author":"Inoue","year":"2019","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.jdiacomp.2025.109068_bb0110","doi-asserted-by":"crossref","first-page":"467","DOI":"10.5551\/jat.40873","article-title":"Dapagliflozin reduces fat mass without affecting muscle mass in type 2 diabetes","volume":"25","author":"Sugiyama","year":"2018","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jdiacomp.2025.109068_bb0115","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/jdi.12851","article-title":"Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (Luseogliflozin: the components of weight loss in Japanese patients with type 2 diabetes mellitus) study","volume":"10","author":"Sasaki","year":"2019","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.jdiacomp.2025.109068_bb0120","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s13340-021-00512-7","article-title":"Two-year administration of sodium-glucose co-transporter 2 inhibitor brought about marked reduction of body fat independent of skeletal muscle amount or glycemic improvement in Japanese patients with type 2 diabetes","volume":"13","author":"Sakamoto","year":"2022","journal-title":"Diabetol Int"},{"issue":"12","key":"10.1016\/j.jdiacomp.2025.109068_bb0125","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1111\/dom.15249","article-title":"Efficacy and safety of the sodium-glucose co-transporter-2 inhibitor empagliflozin in elderly Japanese adults (\u226565 years) with type 2 diabetes: a randomized, double-blind, placebo-controlled, 52-week clinical trial (EMPA-ELDERLY)","volume":"25","author":"Yabe","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.jdiacomp.2025.109068_bb0130","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1111\/jdi.14054","article-title":"Changes in glycemic control and skeletal muscle mass indices after dapagliflozin treatment in individuals with type 1 diabetes mellitus","volume":"14","author":"Yoshimura","year":"2023","journal-title":"J of Diabetes Invest"},{"key":"10.1016\/j.jdiacomp.2025.109068_bb0135","doi-asserted-by":"crossref","unstructured":"Koufakis, T, Doumas, MN, Bargiota, A, Kotsa, K, Maltese, G. Sodium-glucose cotransporter 2 inhibitors in frail, older people with type 2 diabetes and heart fail: do we have enough evidence to confidently support the use?. Expert Rev Clin Pharmacol, 16:9, 771-774.","DOI":"10.1080\/17512433.2023.2247977"},{"key":"10.1016\/j.jdiacomp.2025.109068_bb0140","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.diabres.2017.11.016","article-title":"Increased sugar intake as a form of compensatory hyperphagia in patients with type 2 diabetes under dapagliflozin treatment","volume":"135","author":"Horie","year":"2018","journal-title":"Diabetes Res Clin Pract"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872725001217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872725001217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T07:04:22Z","timestamp":1749884662000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872725001217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1056872725001217"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2025.109068","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Age different effects of SGLT2 inhibitors on body composition in individuals with type 2 diabetes: A retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2025.109068","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors.","name":"copyright","label":"Copyright"}],"article-number":"109068"}}